|
What was that about horse paste again?
|
From one of the only decent sources of Canadian news these days, Small Dead Animals, (the other one being Blazing Cat Fur) there is news of a new study.
The abstract:
We have previously demonstrated that ivermectin used as prophylaxis
for coronavirus disease 2019 (COVID-19), irrespective of the regularity,
in a strictly controlled citywide program in Southern Brazil (ItajaĆ,
Brazil), was associated with reductions in COVID-19 infection,
hospitalization, and mortality rates. In this study, our objective was
to determine if the regular use of ivermectin impacted the level of
protection from COVID-19 and related outcomes, reinforcing the efficacy
of ivermectin through the demonstration of a dose-response effect.
The results are quite profound.
Results
Among 223,128 subjects from the city of ItajaĆ, 159,560 were 18 years
old or up and were not infected by COVID-19 until July 7, 2020, from
which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin.
Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg)
and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548
participants were not included in the analysis. COVID-19 infection rate
was 49% lower for regular users (3.40%) than non-users (6.64%) (risk
rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than
irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001).
The infection rate was 32% lower for irregular users than non-users (RR:
0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants,
regular users were older and had a higher prevalence of type 2
diabetes and hypertension than irregular and non-users. After PSM, the
matched analysis contained 283 subjects in each group of non-users and
regular users, between regular users and irregular users, and 1,542
subjects between non-users and irregular users. The hospitalization rate
was reduced by 100% in regular users compared to both irregular users
and non-users (p < 0.0001), and by 29% among irregular users compared
to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate
was 92% lower in regular users than non-users (RR: 0.08; 95% CI:
0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95%
CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower
mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p =
0.049). Risk of dying from COVID-19 was 86% lower among regular users
than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower
than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while
irregular users had a 51% reduction compared to non-users (RR: 0.49; 95%
CI: 0.32-0.76; p = 0.001).
Conclusion
Non-use of ivermectin was associated with a 12.5-fold increase in
mortality rate and a seven-fold increased risk of dying from COVID-19
compared to the regular use of ivermectin. This dose-response efficacy
reinforces the prophylactic effects of ivermectin against COVID-19.
Hospitalization rate reduced by 100% in regular users, that's a big deal. I've never seen a number like that in a study before. So either they're just lying, or they hit the jackpot. There is no indication at this time that they are lying, by the way.
And now a reminder, Ivermectin is banned in Canada. Your doctor will lose their license to practice if they prescribe Ivermectin to you for the WuFlu. You cannot order it from abroad, her Majesty's Customs will stop it at the border. They're spending a lot of money and burning good will by the truckload to make sure you can't get this stuff.
Your tax dollars at work, ladies and gentlemen.